A growing body of evidence suggests that breast cancer recurrence risk is linked to lifestyle behaviors. This study examined correlations between breast cancer recurrence, risk reduction beliefs, and related behaviors among African American breast cancer survivors (AA BCSs). Study participants included 191 AA BCSs, mean age = 56.3 years, who completed a lifestyle assessment tool. Most respondents believed that being overweight (52.7%), lack of physical activity (48.7%), and a high fat diet (63.2%) are associated with breast cancer recurrence. Over 65% considered themselves overweight; one third (33.5%) agreed that losing weight could prevent recurrence, 33.0% disagreed, while the remaining 33.5% did not know; and nearly half (47.9%) believed that recurrence could be prevented by increasing physical activity. Almost 90% survivors with BMI < 25 Kg/M2 reported no recurrence compared to 75.7% with BMI ≥ 25 Kg/M2 (p = 0.06); nearly all of the women (99.2%) answered
Purpose: To investigate clinicopathological features in patients with recurrent colorectal cancer within 1 year and more than 1 year after curative resection. Materials and Methods: We retrospectively evaluated 103 patients with disease recurrence before versus after 1 year of resection. Thirty-two patients (31%) were diagnosed with recurrence less than 1 year after curative resection for colorectal cancer (early recurrence) and 71 (69%) after more than 1 year (non-early recurrence). Results: The early recurrence group displayed a significantly lower overall survival rate for both colon cancer (p=0, 01) and rectal cancer (p|0.001). Inadequate lymph node dissection was a significant predictor for early relapse. There were no statistically significant differences in clinicopathological variables such as age, sex, primary tumor localization, stage, depth of invasion, lymphovascular invasion and perineural invasion between the early and non-early recurrence groups. However, a K-ras mutation subgroup was
While previous research has shown that consumption of alcohol is associated with an increased risk of breast cancer, there have been limited studies about alcohols role in patient prognosis and survival among those already diagnosed with breast cancer.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes Yehoda M Martei,1 Jennifer M Matro1,21Department of Medicine, Hematology-Oncology Division, 2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USAAbstract: Identifying patients at high risk of breast cancer recurrence has important implications not only for enabling the ability to provide accurate information to patients but also the potential to improve patient outcomes. Patients at high recurrence risk can be offered appropriate treatment to improve the overall survival. However, the major challenge is identifying patients with early-stage breast cancer at lower risk who may be spared potentially toxic therapy. The successful integration of molecular assays into clinical practice may address the problem of overtreatment and improve overall patient outcomes.Keywords: breast cancer, early stage, genomic assays, recurrence risk, recurrence score
Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine.
WEDNESDAY, Sept. 11 (HealthDay News) -- Researchers say theyve identified a genetic indicator of the long-term risk of breast cancer recurrence.. They compared three gene signature methods of predicting the risk of recurrence in patients treated for estrogen-receptor (ER)-positive breast cancer. They found that only the breast cancer index (BCI) -- a "biomarker" based on the expression levels of seven tumor-specific genes -- accurately identifies patients who continues to be at risk for breast cancer recurrence after five years of treatment with either tamoxifen or anastrozole, a drug in the aromatase inhibitor class.. The other two methods examined in the study were the Oncotype Dx Recurrence Score, the current gold standard for guiding clinical decision making, and the ICH4 gene signature, which is used less frequently used.. All three methods were able to predict recurrence risk in the first five years, but only the breast cancer index was able to accurately assess long-term recurrence risk, ...
TY - JOUR. T1 - Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. AU - Aalders, Kim C.. AU - Postma, Emily L.. AU - Strobbe, Luc J.. AU - van der Heiden-van der Loo, Margriet. AU - Sonke, Gabe S.. AU - Boersma, Liesbeth J.. AU - van Diest, Paul J.. AU - Siesling, Sabine. AU - van Dalen, Thijs. PY - 2016. Y1 - 2016. N2 - Purpose: The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes.Patients and Methods: Women , 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were ...
The second type of recurrence is regional in nature. By regional we mean that the cancer has come back outside of the original breast and lymph node area. This is considered to be more serious than a local recurrence, but not as serious as a distant recurrence. The areas in which regional spread of the disease occur include the chest muscles (pectoral), the lymph nodes surrounding the neck area, the internal breast lymph nodes in the breast bone and rib areas and in the lymph nodes above the collarbone. This type of recurrence is rare. The third and most serious type of recurrence is called a distant recurrence. This is also referred to as a metastasis. The areas where distant spread can occur are most likely to occur are bone (25%), liver, brain, bone marrow, lungs or other organs. Sometimes this is referred to as metastatic disease or Stage IV breast cancer. The survival rate becomes much lower once metastasis occurs, with a life expectancy of 18 months on the average after discovering it. ...
To the best of our knowledge, the present study is the first to investigate the frequency and prognostic value of ALDH1 expression in IBTR tissues. The cut-off level for the classification of positive ALDH1 expression was set at ,1% in the current study, as there is no standardized cut-off level or method currently available. The ALDH1 positive cells were counted in hot spots, and positive ALDH1 expression was detected in 20% of the primary tumor samples and 23% of the IBTR tissue samples. The frequency of patients with ALDH1-expressing primary breast cancer (20%) in the current study was similar to that observed in previous studies (19, 17.5%) (10,11); however, the ALDH1 expression the in IBTR group (23%) was higher. It was hypothesized that this variation was due to the dissimilarities between the IBTR and primary tumors. IBTRs included new primary tumors and true recurrences following adjuvant therapy. Therefore, ALDH1-positive cancer stem cells within true recurrence were able to survive ...
There was no statistical difference in the 8 year local recurrence free survival in patients with VNPI scores of 3 or 4, regardless of whether or not radiation therapy was used (100% vs. 97%; P = not significant). Patients with VNPI scores of 5, 6, or 7 received a statistically significant 17% local recurrence free survival benefit when treated with radiation therapy (85% vs. 68%; P = 0.017). Patients with scores of 8 or 9, although showing the greatest relative benefit from radiation therapy, experienced local recurrence rates in excess of 60% at 8 years. Conclusions: ...
If there is a concern of a high-grade MCT, then other staging tests include abdominal ultrasonography, with ultrasound-guided aspirates of the liver and spleen, and bone marrow aspirates.. TREATMENT. The recommended treatment for MCTs is surgical excision. In dogs, lateral margins for excisionn should either be 2cm or equal to the maximal diameter of the MCT, whichever is greater, and one fascial layer for deep margins. In difficult locations where there is limited skin available for closure, preoperative biopsy is recommended as only 1 cm margins are required for excision of grade I MCTs and 2 cm margins for grade II MCTs. Local tumor recurrence rates using this approach ranges from 0% to 11%.. Radiation therapy has been recommended for locoregional tumor control in dogs with stage II MCT disease (i.e., dogs with lymph node metastasis) and possibly for the management of dogs with incompletely excised MCTs. Other options for the management of incompletely excised MCTs include monitoring ...
How the Breast Recurrence Score compares to traditional assessment methods, other genomic assays, the Breast DCIS Score, and to genetic tests.
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by Georgetown Lombardi Comprehensive Cancer Center.
TY - JOUR. T1 - Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features. T2 - a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. AU - Rakovitch, E.. AU - Gray, R.. AU - Baehner, F. L.. AU - Sutradhar, R.. AU - Crager, M.. AU - Gu, S.. AU - Nofech-Mozes, S.. AU - Badve, S. S.. AU - Hanna, W.. AU - Hughes, L. L.. AU - Wood, W. C.. AU - Davidson, N. E.. AU - Paszat, L.. AU - Shak, S.. AU - Sparano, J. A.. AU - Solin, L. J.. PY - 2018/6/1. Y1 - 2018/6/1. N2 - Purpose: Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a predictor of LR in E5194 and Ontario DCIS cohort (ODC) after BCS. We combined data from E5194 and ODC adjusting for clinicopathological factors to provide refined estimates of the 10-year risk of LR after treatment by BCS alone. Methods: Data from E5194 and ODC were combined. Patients with positive margins or multifocality ...
Researchers performed a retrospective analysis of 3 cohorts of women with prior history breast cancer and rheumatoid arthritis or inflammatory bowel disease to determine the risk of breast cancer recurrence with methotrexate, anti-TNF inhibitors, and thiopurines.
Reducing carbohydrate intake could reduce the risk of breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor, researchers report. Using an unusual approach, this study
Although cancer doesnt define my life, it has certainly affected it dramatically. In November 2005, I was diagnosed with rectal cancer and treated throughout 2006. Until recently, there was no evidence of disease after treatment. Now, after unsuccessful attempts at palliative chemotherapy (including Avastin), I have opted for home palliative and hospice care. Quality of life is the goal of my treatment program. My unwanted journey thread will continue to document this significant aspect of my life journey ...
A recent study in the journal JAMA Oncology showed that simple lifestyle changes can reduce lung cancer and colorectal cancer in women by 85% and 60%
Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator. Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11 for a total of 4 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a maximum of 1 year past CR.. Patients are followed at 1 month.. PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for stratum B) will be accrued for this study within 1-2 years. ...
Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator. Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11 for a total of 4 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a maximum of 1 year past CR.. Patients are followed at 1 month.. PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for stratum B) will be accrued for this study within 1-2 years. ...
Sigma-Aldrich offers abstracts and full-text articles by [Lih-Chyang Chen, Li-Jie Wang, Nang-Ming Tsang, David M Ojcius, Chia-Chun Chen, Chun-Nan Ouyang, Chuen Hsueh, Ying Liang, Kai-Ping Chang, Chiu-Chin Chen, Yu-Sun Chang].
We studied the effect of postoperative radiotherapy (RT) after breast sector resection for ductal carcinoma in situ (DCIS). The study protocol stipulated radical surgery but microscopically clear margins were not mandatory. We randomised 1,046 operated women to postoperative RT or control between 1987 and 1999. The primary endpoint was ipsilateral local recurrence. Secondary endpoints were contralateral breast cancer, distant metastasis and death. After a median follow-up of 5.2 years (range 0.1-13.8) there were 44 recurrences in the RT group corresponding to a cumulative incidence of 0.07 (95% confidence interval (CI) 0.05-0.10). In the control group there were 117 recurrences giving a cumulative incidence of 0.22 (95% CI 0.18-0.26) giving an overall hazard ratio of 0.33 (95% CI 0.24-0.47, p , 0.0001). Twenty two percent of the patients had microscopically unknown or involved margins. We found no evidence for different effects of RT on the relative risk of invasive or in situ recurrence. ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
Scientists have identified genetic changes that may predict the likelihood of breast cancer relapse in women taking a common type of hormone therapy.
Information for patients with invasive breast cancer (Stage 1-3a) about a genomic test to help determine whether chemotherapy is right for you.
Results from a new prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect lung cancer recurrence about six months before conventional imaging methods found recurrence.
documentclass{article} % this is the default PlanetMath preamble. as your knowledge % of TeX increases, you will probably want to edit this, but % it should be fine as is for beginners. % almost certainly you want these \usepackage{amssymb} \usepackage{amsmath} \usepackage{amsfonts} % need this for including graphics (\includegraphics) \usepackage{graphicx} % for neatly defining theorems and propositions \usepackage{amsthm} % making logically defined graphics %\usepackage{xypic} % used for TeXing text within eps files %\usepackage{psfrag} % there are many more packages, add them here as you need them % define commands here \begin{document} Let $(X, \mathcal{B}, \mu)$ be a probability space, and let $T_i:X \rightarrow X$ be measure-preserving transformations, for $i$ between $1$ and $q$. Assume that all the transformations $T_i$ commute. If $E\subset X$ is a positive measure set $\mu(E)>0$, then, there exists $n \in \mathbb{N}$ such that $$\mu (E \cap T_1^{-n}(E) \cap \cdots \cap T_q^{-n}(E))>0$$ ...
High-spatial-resolution signal enhancement ratio (SER) imaging mayimprove prediction for patients at high risk for disease recurrence anddeath, according to a study in the July issue of Radiology.
Fifty-one patients were male, 32 female. Median age at diagnosis was 63.9 years (range 34.6-80.6). Most patients had a moderately differentiated adenocarcinoma (66.3%) and TNM disease stage IIB (51.8%). Mean SGLT1 score in primary tumors (n=83) was 4.24 (range 0.5-15.0). Mean Bcl-2 score in primary tumors (n=45) was 0.093 (range 0.0-3.0). Patients with high expression of Bcl-2 had significantly higher mean SGLT1 scores than those with lower Bcl-2 expression: 3.07 versus 5.87 (P=0.025). Mean SGLT1 score in metastases and local recurrent cancer was 2.05 (range 0.5-3.5), which was significantly lower than mean SGLT1 score of their respective primary tumors (3.38, P=0.022). Mean DFS is 12.7 months (median 7.0 months). On uni -and multivariate analysis TNM stage and SGLT1 score showed prognostic value (both P=0.021) for DFS. Mean OS is 20.86 months (median 14.0 months). Both on uni -and multivariate analysis TNM stage retained its prognostic value (P=0.012) and a trend was observed for mean SGLT1 ...
Cancer recurrence - Get the facts and learn to cope with the anger, distress and self-doubt you may feel when your cancer returns.
The PORTEC-1 trial has demonstrated that postoperative external beam radiotherapy for stage 1 endometrial cancer significantly increases local control (from 85 to 96%), but has no impact on survival. Salvage therapy for isolated vaginal recurrence, the main site of recurrence in the control group, was effective with a complete remission rate of 89% and actuarial 5-year survival of 65% in the control group. The use of postoperative RT should therefore be limited to the group of patients at sufficiently high risk of locoregional recurrence (15% or over) to warrant the risk of treatment associated morbidity in order to maximize initial local control and relapse-free survival ...
On Tuesday my PET CT came back suggestive of recurrence in the right pelvic sidewall. Because a biopsy at the time of my cancer surgery two years ago told us there were cancer cells there, we knew this day would come. Those cells were sleeping during my remission but appear to have woken up. Getting cancer just as the world goes under with COVID19 is such unimaginable bad luck I can barely comprehend it ...
TT User Setup 7.4.2 introduced support for product margins per market rather than only per flavor. When configuring products that are hosted on more than one gateway flavor per market, you now create only one product margin rather than one for each gateway flavor.. When upgrading from a version prior to 7.4.2, there may be multiple product margins in a market that are already configured for the same product. When the margins are identical for these products, TT User Setup merges them into a single product margin. However, if the product margins are not identical, your TT User Setup administrator must review the conflicts and decide which margin to use. ...
Once cancer treatment is complete it is time to restore and rejuvenate the body by feeding it with the best foods for optimal nutrition.
Results from observational studies in the United States and France suggest that after a person is cured of HCV there is a small and temporary residual ...
這裡紀錄著我的生活點滴:我在想些什麼, 做那些事, 關心何事, 我的得與失, 我對人與自然觀察所得, 網路資訊 撿到寳貝 或是古物回收,... 》如果您是專程特地來訪或是無意中路過, 我誠心歡迎您》多謝您來訪及留言指教》請再來噢! ...
Around 10 per cent of cancer relapses are caused by tissue left behind during surgery. But a speedy hand-held device could help surgeons remove the whole tumour
In the broad market, advancing issues barely edged out decliners by a slim margin on the NYSE while decliners outpaced advancers by more than 5 to 4 on Nasdaq. The broader S&P 500 slipped 2 points to 2,639. Bitcoin leaped $307 to $11,457. ...
The aim of the present analysis was to evaluate the recurrence pattern in patients with recurrent malignant glioma after re-irradiation in combination with bevacizumab as there is limited data on how to optimally choose dose, fractionation and delineation margins. Thirty-one patients with recurrent malignant glioma treated with re-irradiation and bevacizumab after previous chemoradiotherapy (concurrent temozolomide 75 mg/m2/d according to the EORTC/NCIC trial) and [18 F]FET-PET and/or MRI confirmed recurrence were retrospectively analyzed. Bevacizumab was applied twice during fractionated re-irradiation (10 mg/kg, d1 + d15, median 36 Gy, conventionally fractionated). Recurrence patterns were assessed by means of [18 F]FET-PET and/or MRI. Median follow-up was 34.0 months for all patients [95%-CI, 27.7-40.3] and median post-recurrence survival 10.8 months [95%-CI, 9.2-12.4]. Concerning the recurrence patterns, 61.3% of these were located in-field (19 patients), 22.6% were marginal (7 patients) and 16.1%
TY - JOUR. T1 - A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix. T2 - A Gynecologic Oncology Group study. AU - Fiorica, James V.. AU - Blessing, John A.. AU - Puneky, Louis V.. AU - Secord, Angeles Alvarez. AU - Hoffman, James S.. AU - Yamada, S. Diane. AU - Buekers, Thomas E.. AU - Bell, Jeffrey. AU - Schilder, Jeanne M.. PY - 2009/11/1. Y1 - 2009/11/1. N2 - Purpose: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment. Patients and methods: Women entered on study had or failed one prior chemotherapy regimen in addition to radiosensitizing chemotherapy, performance status less than 3, and adequate hematologic, renal, hepatic, and neurological function. Topotecan was infused at 3.0 mg/m2 on days 1, 8, and 15 every 28 days. Results: Twenty-seven patients were enrolled onto this study with 25 evaluable. ...
The 21-gene recurrence score significantly predicted the risk of recurrence and death in node-positive, estrogen receptor-positive patients treated with adjuvant chemoendocrine therapy, but it did not predict benefit from the addition of paclitaxel to the regimen in a subset of patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial,1 according to Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, Professor of Surgery at Northeastern Ohio Universities College of Medicine and Medical Director of the Comprehensive Breast Program at MD Anderson Cancer Center, Orlando, Florida, and Chairman of the Breast Committee of the NSABP Operations and Biostatistical Center, Pittsburgh, Pennsylvania.. Study Goals. The goal of this substudy was to evaluate the recurrence score as a predictor of the risk of local-regional recurrence in node-positive, estrogen receptor-positive patients treated with adjuvant endocrine therapy and chemotherapy. The secondary goal was to evaluate ...
TY - JOUR. T1 - Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. AU - Dócs, Ottó. AU - Fazakas, Ferenc. AU - Horváth, Nóra Lugosiné. AU - Tóth, L.. AU - András, C.. AU - Horváth, Z.. AU - Méhes, G.. PY - 2014/9/24. Y1 - 2014/9/24. N2 - Colorectal cancer (CRC) is a heterogeneous disease presenting with a wide spectrum of morphological and molecular characteristics sometimes even within the same patient. To understand the mechanisms of oscillations in the KRAS status we evaluated the collective of CRC patients tested using allele-specific PCR and Sanger-sequencing. Mutant KRAS allele was observed in 43.3 % of cases. Repeated analysis of KRAS status in recurrent tumors or metastases was performed in 18/665 cases and a total of 6 cases with different KRAS status was found. In three cases the histological pattern of the tumor was identical. In one patient different histology and molecular status was seen between the primary and the recurrent tumor samples. ...
The purpose of this study is to determine the activity of SCH 717454 in patients with relapsed or recurrent colorectal cancer.
Of the 449 patients who received neoadjuvant chemotherapy, 98 underwent breast-conserving surgery. The average diameter of the tumors was 5.3 cm, and 87.2% reached a size of up to 3 cm. Moreover, 86.7% were classified as clinical stage III, 74.5% had T3-T4 tumors, 80.5% had N1-N2 axilla, and 89.8% had invasive ductal carcinoma. A pathologic complete response was observed in 27.6% of the tumors, and 100.0% of samples had free margins. The 5-year actuarial overall survival rate was 81.2%, and the mean follow-up was 72.8 months. The rates of ipsilateral breast tumor recurrence and locoregional recurrence were 11.2% and 15.3%, respectively. Multifocal morphology response was the only factor related to ipsilateral breast tumor recurrence disease-free survival ...
The management of rectal cancer has changed in many countries over the last two decades and resulted in improved survival for the majority of rectal cancer patients. In this thesis some surgical strategies and histopathological aspects to improve and clarify the management of rectal cancer patients are investigated.. Even in the era of TME surgery and radiotherapy, a higher local recurrence rate and shorter survival for rectal cancer patients operated with abdominoperineal resection is reported. In the first paper we describe a new strategy with partial anterior en bloc resection of either the prostate or the vagina, resulting in very low local recurrence rates and excellent long-term survival. Histopathological examination of the specimen lays the foundation for decision making on oncological therapy. A positive circumferential resection margin (CRM) has, in previous papers, been related to a high risk of local recurrence. In the second paper we show that a CRM ≤ 1 mm was not correlated with ...
Statins and risk of breast cancer recurrence Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1 1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had
Read "Erratum to: Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review, World Journal of Urology" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Six modern, prospective, randomized trials have demonstrated that breast-conserving therapy (lumpectomy followed by radiation) offers survival rates equivalent to mastectomy (Table 61-1)1-7; however, when negative margins are not achieved or when radiation therapy is not pursued, breast conservation is associated with higher rates of local recurrence (Tables 61-1 and 61-2).1,2,8-14 Until recently, the impact of local recurrence on survival remained unclear. In 2005, the Early Breast Cancer Trialists Collaborative Group (EBCTCG) published the results of a large meta-analysis combining all individual patient data for 42,080 women who collectively took part in 78 treatment comparisons (more vs less surgery, more surgery vs radiotherapy, radiotherapy vs none) to determine the impact of local recurrence on survival. Specifically, among 10 breast-conservation trials included in the EBCTCG analysis (7311 women), postoperative radiation treatment (XRT) was associated with a statistically significant ...
TY - JOUR. T1 - Predicting the risk of locoregional recurrence after early breast cancer. T2 - an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. AU - Voelkel, Vinzenz. AU - Draeger, Teresa Maria Cornelia. AU - Oudshoorn, C. AU - de Munck, Linda. AU - Hueting, Tom. AU - Gerken, Michael. AU - Klinkhammer-Schalke, Monika. AU - Lavric, Miha AU - Siesling, Sabine N1 - Springer deal. PY - 2019/7/1. Y1 - 2019/7/1. N2 - Purpose: Follow-up after breast cancer treatment aims for an early detection of locoregional breast cancer recurrences (LRR) to improve the patients outcome. By estimating individuals 5-year recurrence-risks, the Dutch INFLUENCE-nomogram can assist health professionals and patients in developing personalized risk-based follow-up pathways. The objective of this study is to validate the prediction tool on non-Dutch patients. Material and methods: Data for this external validation derive from a large clinical cancer registry in ...